Prot# NN9536-4374: Effect and Safety of Semaglutide 2.4 mg Once-Weekly in Subjects with Overweight or Obesity and Type 2 Diabetes

Project: Research project

Project Details

StatusFinished
Effective start/end date6/25/18 → 6/25/21

Funding

  • DrugDev Inc. (NN9536-4374 // NN9536-4374)
  • Novo Nordisk Inc. (NN9536-4374 // NN9536-4374)